J&J Medical Connect
TREMFYA®

(guselkumab)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA - Use in Adult Patients with Fistulizing Crohn's Disease

Last Updated: 11/17/2026

SUMMARY

  • The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
  • A phase 3 randomized clinical trial is ongoing to evaluate the efficacy and safety of TREMFYA in fistulizing, perianal Crohn’s disease (CD). Additional details are available at clinicaltrials.gov: NCT05347095. Results up to week 48 are reported below.1-4

clinical data

FUZION Study

FUZION (NCT05347095) is a phase 3, randomized, double-blind, placebo (PBO)-controlled, multicenter study evaluating the efficacy and safety of TREMFYA in adult patients with active perianal fistulizing CD.1

Study Design/Methods

  • Patients enrolled in this study met the following criteria:
    • Adults with ≥1 active draining perianal fistula confirmed by blinded central magnetic resonance imaging (MRI) review
    • Crohn’s Disease Activity Index (CDAI) <350
    • Intolerance or an inadequate response to oral corticosteroids, 6-mercaptopurine, azathioprine, methotrexate, or up to 2 advanced-therapy classes (anti-tumor necrosis factor [TNF] agents, vedolizumab, or Janus kinase inhibitors [JAKi]) and be refractory to antibiotics (ie, ciprofloxacin and metronidazole)
  • The study design is presented in Figure: FUZION Study Design.

FUZION Study Design1

Abbreviations: CS, corticosteroid; GUS, guselkumab; IV, intravenous; MRI, magnetic resonance imaging; PBO, placebo; PE, primary endpoint; Q4W, every 4 weeks; Q8W, every 8 weeks; R, randomization; SC, subcutaneous; U, study unblinding.
aDuring screening, fistula-related surgery and use of antibiotics were allowed according to local practice.

  • During the extension treatment phase, non-responders across all treatment arms received 1 blinded dose escalation adjustment. Non-responder was defined as <50% reduction from baseline in the number of open or draining fistulas at week 24. Responders continued with the same treatment and dose regimen through week 48.
  • The primary endpoint was the combined fistula remission at week 24.
    • Combined fistula remission was defined as: (1) clinically assessed fistula remission: 100% closure of all treated external openings with no new fistulas or abscesses and no drainage from external openings (either spontaneous or upon gentle finger compression); and (2) radiologically assessed fistula remission: absence of perianal fistula collections >2 cm, as confirmed by blinded central review of MRI results.
  • Multiplicity-controlled secondary endpoints were clinically assessed fistula remission at week 24 and clinically assessed fistula response (defined as a ≥50% reduction from baseline in the number of open or draining perianal fistulas) at week 24.
  • Other secondary endpoints were: clinically assessed fistula response at week 12, combined fistula remission at week 48, clinically assessed fistula remission at week 48, and clinically assessed fistula response at week 48.
  • Additionally, changes from baseline to week 24 in Magnetic Resonance Novel Index for Fistula Imaging in Crohn’s Disease (MAGNIFI-CD) MRI-based score were also assessed.

Results

  • Among 286 patients in the full analysis set, 113 received TREMFYA 100 mg SC Q8W, 115 received TREMFYA 200 mg SC Q4W and 58 received PBO; 90% of patients receiving TREMFYA and 84% receiving PBO completed 48 weeks of therapy.4
  • Baseline characteristics are summarized in Table: Demographics and Baseline Characteristics - FUZION Study.

Demographics and Baseline Characteristics - FUZION Study4
Characteristic
TREMFYA 100 mg SC Q8W (N=113)
TREMFYA 200 mg SC Q4W (N=115)
PBO
(N=58)

Age, years, mean (SD)
36.2 (12.7)
36.0 (13.0)
38.0 (12.9)
Crohn’s disease duration, years, median (IQR)
5.6
(1.9-15.6)

6.8
(2.1-15.9)

7.8
(3.4-17.6)

CDAI score, n
113
108
56
   Mean (SD)
154.6 (97.6)
143.2 (84.6)a
147.6 (104.3)b
   >220, n (%)
25 (22)
23 (21)
10 (8)
   ≤220, n (%)
88 (78)
85 (79)
46 (82)
Patients with open or draining fistula, n (%)
   1 fistula
73 (65)
60 (52)
33 (57)
   ≥2 fistulas
40 (35)
55 (48)
25 (43)
Fistula-related surgery during screening, n (%)
17 (15)
18 (16)
7 (12)
Patients with collections >2 cm, n (%)
0
4 (3)
2 (3)
Abbreviations: CDAI, Crohn’s Disease Activity Index; IQR, interquartile range; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous; SD, standard deviation.
aN=108
bN=56

Efficacy

Combined Fistula Remission at Week 24 and Week 484

P-values at week 24 were multiplicity-controlled, except for the GUS combined group, which was nominal; therefore, statistical significance has not been established for those endpoints.
Abbreviations: CI, confidence interval; GUS, guselkumab; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous.
Note: After applying the intercurrent event strategy, missing data were imputed as not achieving binary endpoints.
a
GUS combined group included both maintenance-dose regimens administered from week 12 through week 24.
bNon-responder PBO patients received GUS after week 24; therefore, no PBO arm was maintained beyond week 24.

Secondary Endpoints: Clinically Assessed Fistula Remission and Clinically Assessed Fistula Response through Week 484

P-values at week 24 were multiplicity controlled, except for the GUS combined group, which was nominal.  Additionally,
P-value at week 12 was nominal; therefore, statistical significance has not been established for those endpoints
Abbreviations
: CI, confidence interval; GUS, guselkumab; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous.
Note: After applying the intercurrent event strategy, missing data were imputed as not achieving binary endpoints.
aGUS 200 mg IV was administered as induction therapy at weeks 0, 4, and 8.
bAt week 48, the GUS 100 mg SC Q8W group comprised responders on 100 mg SC Q8W and non-responders whose dose was adjusted to 200 mg SC q4w at week 24.
cGUS combined comprised both maintenance dose arms from week 12 through week 48.
dNon-responder PBO patients received blinded GUS after week 24; therefore, no PBO arm was maintained beyond week 24.


Combined Fistula Remission, Clinically Assessed Fistula Remission, and MAGNIFI-CD Outcomes at Week 242
TREMFYA SC 100 mg Q8W
TREMFYA SC 200 mg Q4W
PBO
Combined fistula remissiona
   Subgroup: CDAI ≥220 at baseline,
   n/N (%)

8/27 (30)
5/24 (21)
0/9 (0)
      Adjusted rate difference (95% CI)
29.6 (12.4 to 46.9)
20.8 (4.6 to 37.1)
-
Subgroup: with prior biologic
   exposure at baseline, n/N (%)

15/70 (21)
22/77 (29)
2/42 (5)
  • Adjusted rate difference (95% CI)
16.7 (5.2 to 28.1)
23.8 (11.8 to 35.7)
-
Subgroup: with proctitis at baseline,
   n/N (%)

8/31 (26)
10/37 (27)
2/16 (12)
Adjusted rate difference (95% CI)
13.9 (-8.2 to 36.0)
14.4 (-6.9 to 35.8)
-
Subgroup: without proctitis at
   baseline, n/N (%)

24/82 (29)
21/78 (27)
4/42 (10)
Adjusted rate difference (95% CI)
19.0 (6.2 to 31.7)
17.4 (4.4 to 30.4)
-
Clinically assessed fistula remissionb
   Overall population, n/N (%)
32/113 (28)
31/115 (27)
6/58 (10)
      Adjusted rate difference (95% CI)
18.0 (7.0 to 29.0)
16.6 (5.6 to 27.6)
-
      P-value
0.007
0.013
-
MAGNIFI-CD
   Overall population, (N=112)
LS mean change from
      baseline (95% CI)

-1.4 (-1.9 to -0.8)
-1.7 (-2.3 to -1.2)
-0.4 (-1.1 to 0.4)
      LS mean difference (95% CI)
-1.0 (-1.9 to -0.1)
-1.4 (-2.3 to -0.5)
-
Nominal P-value
0.034c
0.004c
-
Note: Missing data imputation: After applying the ICE strategy, patients with missing data were imputed as not having achieved binary endpoints or not experiencing an improvement from baseline for continuous endpoints. P-values associated with MAGNIFI-CD LS means are nominal and P values are based on a CMH test for binary endpoints and MMRM for continuous endpoints.
Abbreviations: CDAI, Crohn’s Disease Activity Index; CI, confidence interval; CMH, Cochran-Mantel-Haenszel; ICE, intercurrent event; LS, least squares; MAGNIFI-CD, Magnetic Resonance Novel Index for Fistula Imaging in Crohn’s Disease; MMRM, mixed model for repeated measure; MRI, magnetic resonance imaging; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SC, subcutaneous.
aCombined fistula remission is defined as 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by external openings (occurring spontaneously or after gentle finger compression) and absence of collections >2 cm of the perianal fistulas in at least 2 of 3 dimensions, confirmed by a blinded central review of MRI result.
bClinically assessed fistula remission is defined as 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by external openings, occurring spontaneously or after gentle finger compression.
cNominal P-value for TREMFYA vs PBO. The endpoint was not controlled for multiple comparisons. Therefore, the P-value is nominal and statistical significance has not been established.

Safety

  • Through week 48, no opportunistic infections, anaphylactic reactions, major adverse cardiovascular events, clinically important hepatic disorders, venous thromboembolic events, or active tuberculosis were reported. There were 2 cases of malignancies (plasmablastic lymphoma and non-melanoma skin cancer; assessed by the investigator as unrelated to study treatment) reported in the GUS 200 mg SC group.4
  • There were no reported cases of additional advserse events of interest (anaphylactic reactions, opportunistic infections, major adverse cardiovascular events, venous thromboembolisms, active tuberculosis, or clinically important hepatic disorders).
  • For adverse events, see Table: Summary of AEs through Week 48.

Summary of AEs through Week 484
TREMFYA SC 100 mg Q8W
(N=113)

TREMFYA SC 200 mg Q4W
(N=115)

PBO
(N=58)

Duration of follow-up, weeks, mean
33.6
33.6
28.7
Exposure (number of study agent administrations), mean
8.4
8.5
6.9
≥1 AE, n (%)
80 (71)
88 (77)
48 (83)
≥1 SAE, n (%)
18 (16)
9 (8)
8 (14)
≥1 AE leading to discontinuation of study agent, n (%)
8 (7)
5 (4)
5 (9)
≥1 infection, n (%)
52 (46)
41 (36)
28 (48)
≥1 anal abscess, n (%)
13 (12)
6 (5)
3 (5)
≥1 serious infection, n (%)
13 (12)
2 (2)
2 (3)
≥1 serious gastrointestinal disorders, n (%)
5 (4)
3 (3)
4 (7)
Death, n
0
0
0
Abbreviations: AE, adverse event; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SAE, serious adverse event.

Case Report

Croitoru et al (2022)3 described the case of a 43-year-old male patient with a history of fistulizing CD and who was referred for suspected hidradenitis suppurativa (HS).

  • The patient was diagnosed with CD due to a 5-year presentation of weight loss and diarrhea, confirmed by endoscopic assessment. His CD progressed to pancolitis involving the rectum with multiple draining fistulas.
  • After failing multiple treatments, including antibiotics, mesalamine, azathioprine, and various TNF inhibitors, he underwent surgical intervention initially with loop ileostomy, but his perianal disease continued to persist.
  • Over the next year, the patient was treated with ustekinumab but developed pancolitis. This led to initiation of methylprednisolone treatment, bridged to a modified total proctocolectomy with end ileostomy. Perianal dissection was foregone, and a small stump was left in place.
  • Over the following months, the patient was put on steroid taper and later treated with a TNF inhibitor. Addition of sulfasalazine, methotrexate, hyperbaric oxygen, and concurrent intralesional steroids minimally benefited.
  • The arrangement of draining tract and inflammatory nodules led to suspicion for concomitant HS and the patient was referred to dermatology clinic for evaluation and management.
    • Upon further examinations, there were deep ulcerated fissures in the bilateral groin with linear sinuses with peripheral erosions and fibrinoid changes at the wound. There were also many tender and deep nodules and subcutaneous abscesses adjacent ulcers, which extended perianally. The patient described ongoing weight loss, without fever, and abdominal pain and minimal change in stoma output.
    • Given the patient's history of fistulizing CD and extensive wounds, it was suspected that he had ongoing occult inflammatory intestinal disease and fistulation to skin. MRI of the pelvis showed an intramural abscess in the most superior aspect of the rectal stump and multiple emanating fistulas.
    • Treatment with ertapenem drastically reduced perianal pain and discharge and the patient was subsequently started on TREMFYA 100 mg every 8 weeks.
    • Within 6 months of initiating TREMFYA, the patient experienced near complete resolution of all inflammatory nodules and abscesses with significant weight gain and improvement of the bilateral perineal ulcerations to near resolution. His serum C-reactive protein levels decreased from baseline (60 to 8.3).
    • Repeated MRI of the pelvis and abdomen showed interval resolution and improvement of multiple intestinal fistulas with reduction in size of intramural abscess. The patient underwent multidisciplinary re-evaluation for surgical candidacy to remove the remaining portion of his rectal stump.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 11 September 2026.

 

References

1 Peyrin-Biroulet L, Jairath V, Hart A, et al. Guselkumab for perianal fistulizing Crohn’s disease: week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study. Oral Presentation presented at: Digestive Disease Week (DDW); May 3-5, 2026; Chicago, IL.  
2 Sands BE, Hart A, Jairath V, et al. Efficacy of guselkumab in perianal fistulizing Crohn’s disease: week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study. Abstract presented at: American College of Gastroenterology (ACG) conference; October 9-14, 2026; Nashville, Tennessee.  
3 Croitoru D, Seigel K, Nathanielsz N, et al. Treatment of severe hidradenitis Suppurativa and Fistulizing Crohn’s disease with Guselkumab. [published online ahead of print March 08, 2022]. J Eur Acad Dermatol Venereol. 36:e497-e594. doi:10.1111/jdv.18033.  
4 Ailsa Hart, Axel Dignass, Vipul Jairath, et al. Efficacy and safety of guselkumab in perianal fistulizing Crohn’s disease: week 48 results from the phase 3, randomized, double-blind, placebo-controlled FUZION trial. Oral presentation presented at: UEGW; October 17-20, 2026; Barcelona, Spain.  

Would you like to clear and leave your conversation? Message history will be lost.